Table 2.
Complications and prognosis of all patients in the control and ruxolitinib groups (N = 55).
| Control (n = 14) | Ruxolitinib (n = 41) | χ2 | P value | |
|---|---|---|---|---|
| aGVHD (n, %) | 3.980 | 0.046 | ||
| Yes | 7 (50.0) | 9 (22.0) | ||
| No | 7 (50.0) | 32 (78.0) | ||
| Grade II–IV aGVHD (n, %) | 6.132 | 0.013 | ||
| Yes | 6 (42.9) | 5 (12.2) | ||
| No | 8 (57.1) | 36 (87.8) | ||
| Grade III-IV aGVHD (n, %) | 4.245 | 0.039 | ||
| Yes | 4 (28.6) | 3 (7.3) | ||
| No | 10 (71.4) | 38 (92.7) | ||
| cGVHD (n, %) | 0.002 | 0.960 | ||
| Yes | 4 (28.6) | 12 (29.3) | ||
| No | 10 (71.4) | 29 (70.7) | ||
| Severe cGVHD (n, %) | 0.716 | 0.398 | ||
| Yes | 3 (21.4) | 5 (12.2) | ||
| No | 11 (78.6) | 36 (87.8) | ||
| Hemorrhagic cystitis (n, %) | 0.006 | 0.937 | ||
| Yes | 7 (50.0) | 21 (51.2) | ||
| No | 7 (50.0) | 20 (48.8) | ||
| Pulmonary infection (n, %) | 0.076 | 0.783 | ||
| Yes | 9 (64.3) | 28 (68.3) | ||
| No | 5 (35.7) | 13 (31.7) | ||
| Intestinal infection (n, %) | 1.725 | 0.189 | ||
| Yes | 6 (42.9) | 10 (24.4) | ||
| No | 8 (57.1) | 31 (75.6) | ||
| EBV infection (n, %) | 0.000 | 0.983 | ||
| Yes | 1 (7.1) | 3 (7.3) | ||
| No | 13 (92.9) | 38 (92.7) | ||
| CMV infection (n, %) | 0.002 | 0.967 | ||
| Yes | 11 (78.6) | 32 (78.0) | ||
| No | 3 (21.4) | 9 (22.0) | ||
| Relapse (n, %) | 0.352 | 0.553 | ||
| Yes | 3 (21.4) | 6 (14.6) | ||
| No | 11 (78.6) | 35 (85.4) | ||
| Death (n, %) | 0.487 | 0.485 | ||
| Yes | 8 (57.1) | 19 (46.3) | ||
| No | 6 (42.9) | 22 (53.7) | ||
| Nonrelapse mortality (n, %) | 0.317 | 0.574 | ||
| Yes | 6 (42.9) | 16 (39.0) | ||
| No | 2 (14.3) | 3 (7.3) |
CMV Cytomegalovirus, EBV Epstein-Barr virus, GVHD graft-versus-host disease.